Drug Efficacy in Animal Models

CDAS conducts comprehensive in vivo drug efficacy studies as part of its preclinical contract research offering. Our programs will allow you to assess the therapeutic efficacy of lead compounds or drug development candidates and to uncover potential side effects caused by the administration of such compounds.

We have established numerous oncology animal models to assess anti-cancer therapies over the course of treatment in vivo. Our models include a wide range of spontaneous, syngeneic, and xenogeneic oncology models particularly useful for cost effective, rapid, and reliable in vivo drug screening and drug efficacy confirmation studies.

Caliper's IVIS in vivo imaging system offers exceptional sensitivity through detecting fluorescent and bioluminescent signals emitted by only a few cells in a live animal. IVIS-based imaging studies provide high quality data and more accurate and clinically relevant predictions earlier in preclinical drug development process. Non-invasive, bioluminescent imaging of tumor growth and metastasis allows longitudinal evaluation of tumor development before, during, and after treatment, offering an excellent preclinical strategy to assess tumor response and recurrence.

Our oncology drug efficacy research program is fully modular and can be tailored to meet investigators’ needs. Typical efficacy study parameters considered are:

• Determination of optimum drug testing conditions
  -  Acute toxicology
  -  Pharmacokinetic/Pharmacodynamic profile
  -  Dosing frequencies
  -  Chronic toxicology and tolerability

• Optical imaging and physical measurements

• Choice of animal model

• Drug treatment protocol including route of administration

• Imaging schedule